Karen McLean
Professor
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (14)
Year:
2026
Year:
2026
Cyclin-dependent kinase 2 (CDK2) inhibitors have recently been developed and have entered clinical trials. Combination approaches can help broaden the use of therapeutic agents and establish more effective treatments. Here, we evaluated the selective CDK2 inhibitor BLU-222 for mechanisms of response in the context of ovarian and breast cancer models. Sensors of cellular CDK activity indicated that sensitivity to either CDK4/6 or CDK2 inhibition was related to the differential dependence on a single CDK for G1–S transition. Unlike CDK4/6 inhibitors, BLU-222 was able to robustly inhibit proliferation through cell-cycle inhibition in both G1 and G2 phases. However, it remained possible for cells to reenter the cell cycle upon drug withdrawal. The antiproliferative strength and impact on G1–S versus G2–M accumulation was mediated by the RB tumor suppressor. To broaden the sensitivity to CDK2 inhibition, combinatorial drug screens were performed that identified both synergistic (e.g., CDK4/6 inhibitors) and antagonistic (e.g., WEE1 inhibitors) relationships. Models that were exceptionally sensitive to CDK2 inhibition displayed coordinate expression of cyclin E1 and P16INK4A, an endogenous CDK4/6 inhibitor. Functional studies demonstrated that P16INK4A and CDK4/6 activity were key mediators of sensitivity to BLU-222. Clinical gene and protein expression analyses revealed a positive correlation between cyclin E1 and P16INK4A and identified that ∼25% of ovarian cancers exhibited coordinate expression of cyclin E, P16INK4A, and RB, indicative of strong sensitivity to CDK2 inhibition. Together, this work advances a precision strategy for the use of CDK2 inhibitors in the context of ovarian and breast cancers. Significance: The CDK2-specific inhibitor BLU-222 shows preclinical efficacy in breast and ovarian cancer with select determinants of response and holds promise in combinatorial strategies. See related article by House and colleagues, p. 1297
Year:
2025
Figure S2. Contextual biochemical response to CDK inhibition. A, Western blot of RB1-E2F pathway activity in OVSAHO and MDA-MB-157 cells following BLU-222 or palbociclib treatment. B, Schematic depicting mVenus-DHB and mCherry-RB CDK activity reporter constructs. C, Representative images of mCherry-RB sensor activity in OVCAR-3 and T-47D cells treated with 500 nM BLU-222 or palbociclib (scale bar = 100 µm). D, Quantification of mCherry-RB CDK activity sensor localization to the cytosol or nucleus in the indicated ovarian and breast cancer cell lines following treatment with either 500 nM BLU-222 or palbociclib. E, Representative images of mCherry-RB sensor activity in OVCAR-3 cells transfected with si NT , si CCNE1 or si CCND1 (scale bar = 100 µm). F, Quantification of mCherry-RB CDK activity sensor localization to the cytosol or nucleus in OVCAR-3 and MDA-MB-157 cells following knockdown of CCNE1 or CCND1 with siRNA constructs.
Year:
2025
Figure S6. P16INK4A is a key determinant of response to BLU-222. A, Heatmap analysis from the cancer dependency map (DepMap) database displaying relative expression of CCNE1 and several endogenous CDK inhibitor genes in a panel of established ovarian and breast cancer cell lines. B, Western blot of RB1-E2F pathway activity in MDA-MB-157 cells following overexpression (OE) of CDK4 with and without BLU-222 treatment. C, Live cell proliferative monitoring of CDK4 WT (left) and overexpressing (OE, right) of MDA-MB-157 cells treated with serial concentrations of BLU-222 [n = 3–4 per group; two-way ANOVA, significance (shown as #) comparing CDK4 OE versus CDK4 WT at 62.5 nM BLU-222 dose; error bars represent SEM]. D, Western blot of RB1-E2F pathway activity in MDA-MB-157 cells following overexpression (OE) of CDK6 with and without BLU-222 treatment. E, Live cell proliferative monitoring of CDK6 WT (left) and overexpressing (OE, right) MDA-MB-157 cells treated with serial concentrations of BLU-222 [n = 3–4 per group; two-way ANOVA, significance (shown as #) comparing CDK6 OE versus CDK6 WT at 250 nM BLU-222 dose; error bars represent SEM]. F, Table summarizing effect of CDK4 or CDK6 overexpression (OE) or CDKN2A knockdown on IC50 to BLU-222 in Kuramochi and MDA-MB-157 cells. G, Hematoxylin and Eosin (H&E) staining and of tumors excised from MDA-MB-157 xenografts in NOD scid gamma (NSG) mice treated with either vehicle or BLU-222; arrows indicate cells with enlarged morphology (scale bar = 100 µm). #, P
Year:
2025
Cyclin-dependent kinase 2 (CDK2) inhibitors have recently been developed and have entered clinical trials. Combination approaches can help broaden the use of therapeutic agents and establish more effective treatments. Here, we evaluated the selective CDK2 inhibitor BLU-222 for mechanisms of response in the context of ovarian and breast cancer models. Sensors of cellular CDK activity indicated that sensitivity to either CDK4/6 or CDK2 inhibition was related to the differential dependence on a single CDK for G 1 –S transition. Unlike CDK4/6 inhibitors, BLU-222 was able to robustly inhibit proliferation through cell-cycle inhibition in both G 1 and G 2 phases. However, it remained possible for cells to reenter the cell cycle upon drug withdrawal. The antiproliferative strength and impact on G 1 –S versus G 2 –M accumulation was mediated by the RB tumor suppressor. To broaden the sensitivity to CDK2 inhibition, combinatorial drug screens were performed that identified both synergistic (e.g., CDK4/6 inhibitors) and antagonistic (e.g., WEE1 inhibitors) relationships. Models that were exceptionally sensitive to CDK2 inhibition displayed coordinate expression of cyclin E1 and P16 INK4A , an endogenous CDK4/6 inhibitor. Functional studies demonstrated that P16 INK4A and CDK4/6 activity were key mediators of sensitivity to BLU-222. Clinical gene and protein expression analyses revealed a positive correlation between cyclin E1 and P16 INK4A and identified that ∼25% of ovarian cancers exhibited coordinate expression of cyclin E, P16 INK4A , and RB, indicative of strong sensitivity to CDK2 inhibition. Together, this work advances a precision strategy for the use of CDK2 inhibitors in the context of ovarian and breast cancers. Significance: The CDK2-specific inhibitor BLU-222 shows preclinical efficacy in breast and ovarian cancer with select determinants of response and holds promise in combinatorial strategies. See related article by House and colleagues, p. 1297
Year:
2025
Figure S5. Cooperative and antagonistic combination strategies with BLU-222. A, BLISS synergistic analysis for antagonism between BLU-222 and CHK1 checkpoint kinase inhibitors in MDA-MB-231 cells (n = 3 per group; BLISS scores calculated with SynergyFinder v3). B, Live cell proliferative monitoring of the indicated cell lines treated with BLU-222, palbociclib, or in combination (n = 3–4 per group; one-way ANOVA; error bars represent SEM). C, Quantification of mVenus-DHB and mCherry-RB CDK activity sensor localization to the cytosol or nucleus in MDA-MB-231 and HCC-1806 cells following treatment with either 500 nM BLU-222, palbociclib, or combination. D, Quantification of mVenus-DHB and mCherry-RB CDK activity sensor localization to the cytosol or nucleus in MDA-MB-231 and HCC-1806 cells following treatment with si CCNE1 , si CCND1 or combination. E, Live-cell imaging endpoint stills for HCC-1806 cells treated for 5 days with 500 nM BLU-222, palbociclib, or combination (scale bar = 100 µm). ns, not significant; *, P
Year:
2025
Figure S4. Loss of RB1 shifts phase of arrest and sensitivity to BLU-222. A, Heatmap of RNA sequencing data comparing differential gene expression between BLU-222-treated Kuramochi (125 nM BLU-222) and OVCAR-8 (250 nM BLU-222) cells normalized to respective DMSO-treated controls. B, Cell cycle profiling from univariate flow cytometric analysis from OVCAR-8 cells at baseline, after 1 to 5 days of treatment with 500 nM BLU-222, and after 1 to 5 days of drug washout. C, Western blot for abrogation of G2/M checkpoint signaling in OVCAR-8 cells following doxycycline (Dox) induction of the RB1 expression vector and treatment with BLU-222 compared with RB1 deficient controls. D, Live cell proliferative monitoring of OVCAR-8 cells following Dox induction of the RB1 expression vector (RB1 Dox +) with non-induced controls (RB1 Dox -) and treatment with serial concentrations of palbociclib (n = 3–4 per group; error bars represent SEM). E, Table summarizing effect of RB1 induction on IC50 to BLU-222 in OVCAR-8 cells. F, Live cell proliferative monitoring of OVCAR-8 cells following doxycycline induction of the RB1 expression vector (RB1 Dox +) with non-induced controls (RB1 Dox -) and transfection with si NT , si CCNE1 , or si CCNA2 [n = 3–4 per group; two-way ANOVA, significance (shown as #) for combined RB1 and siRNA effect; error bars represent SEM]. G, Live-cell imaging endpoint stills for the OVCAR-8 cells in D (scale bar = 100 µm). H, Western blot of RB1-E2F pathway activity in Kuramochi cells with RB1 knockdown or si NT control and treatment with BLU-222. I, Cell cycle profiling from univariate flow cytometric analysis from Kuramochi cells with RB1 knockdown or si NT control and treatment with BLU-222. J, Western blot of RB1-E2F pathway activity in MDA-MB-157 cells with and without deletion (DEL) of RB1 and treatment with BLU-222. K, Cell cycle profiling from univariate flow cytometric analysis from MDA-MB-157 cells with and without deletion (DEL) of RB1 and treatment with BLU-222. L, Table summarizing effect of RB1 knockdown/deletion on IC50 to BLU-222 in Kuramochi and MDA-MB-157 cells, respectively. ####, P
Year:
2025
Supplemental File 1. BLU-222 combinatorial drug screen data from MDA-MB-231 (tab 1) and COV-504 cells (tab 2) reported in Figure 5. Data reported as percent growth compared to sole treatment with 0.1% DMSO.
Year:
2025
Figure S3. BLU-222 elicits potent G1 arrest in Cyclin E1 and P16INK4A-high models expressing RB. A, Cell cycle profiling from univariate flow cytometric analysis from the indicated cell lines following treatment with palbociclib. B, Bivariate flow cytometric analysis from the indicated cell lines following transfection with si NT or si CCNE1 constructs. C, RNA sequencing gene set enrichment plots for E2F targets and interferon alpha response pathways in Kuramochi and MDA-MB-157 cells following treatment with 125 nM BLU-222 or 100 nM, respectively, for 48 hours compared to DMSO-treated controls. PI, propidium iodide; FITC, anti-bromodeoxyuridine fluorescein.
Year:
2025
Year:
2025
Year:
2025
Year:
2024
Year:
2023
Collaborators (4)
Agnieszka Witkiewicz
Professor of Pathology and Oncology
Roswell Park Comprehensive Cancer Center
Erik Knudsen
Chairperson/Associate Director of Basic Science
Roswell Park Comprehensive Cancer Center
Minh Tung Phung
Assistant Professor
University of Wisconsin-Madison
Alice Lee
Associate Professor
California State University Fullerton
Make your next move.
Prepare your application
Review drafts before you send them.